卡铂联合依托泊苷VS托泊替康作为敏感性复
2020-11-29 来源：本站原创 浏览次数：次SCI
17September
Carboplatinplusetoposideversustopotecanassecond-linetreatmentforpatientswithsensitiverelapsedsmall-celllungcancer:anopen-label,multicentre,randomised,phase3trial
Background背景
TopotecaniscurrentlytheonlydrugapprovedinEuropeinasecond-linesettingforthetreatmentofsmall-celllungcancer.Thisstudyinvestigatedwhetherthedoubletofcarboplatinplusetoposidewassuperiortotopotecanasasecond-linetreatmentinpatientswithsensitiverelapsedsmall-celllungcancer.
托泊替康目前是欧洲唯一批准用于治疗小细胞肺癌的二线药物。这项研究调查了在敏感的复发性小细胞肺癌患者中，卡铂联合依托泊苷是否优于托泊替康作为二线治疗。
Methods方法
Inthisopen-label,randomised,phase3trialdonein38hospitalsinFrance,weenrolledpatientswithhistologicallyorcytologicallyconfirmedadvancedstageIVorlocallyrelapsedsmall-celllungcancer,whorespondedtofirst-lineplatinumplusetoposidetreatment,butwhohaddiseaserelapseorprogressionatleast90daysafter
健康热线：